The GTL-16 tumor cell line was chosen because of amplification of the receptor tyrosine kinase c-Met, a client protein of Hsp90, and for its dependency on c-Met for growth and survival (24), MV4; 11 leukemia driven by the tyrosine kinase receptor FLT3ITD mutation, was also analyzed. This evidence concerns the gene HSP90AA1 and leukemia.